Back to Search Start Over

Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.

Authors :
Hattasingh W
Chanthavanich P
Sirivichayakul C
Arunsodsai W
Surangsrirat S
Srisuwannaporn T
Kaewma B
Yoksan S
Limkittikul K
Yang J
Mao Y
Source :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Dec 31; Vol. 18 (1), pp. 2028513. Date of Electronic Publication: 2022 Feb 01.
Publication Year :
2022

Abstract

Japanese encephalitis is the main cause of viral encephalitis in Asia. In a previous single-arm vaccine trial, an inactivated chromatographically purified Japanese encephalitis Vero cell vaccine (CVI-JE; JEVAC <superscript>TM</superscript> ) was safe and immunogenic in 152 Thai children aged 1-3 years receiving a 2-dose primary immunization and booster dose 1 year later. We conducted a 5-year follow-up assessment of the persistence of the immune response the 144 children remaining in this cohort after first booster dose. Immunity was assessed by 50% plaque reduction neutralization test annually for up to 5 years post-booster. Seroprotection rates (95%CI) decreased from 100% (97.1-100) at 1 year post-booster to 93% (85.0-98.3) at 5 years post-booster. No serious vaccine-related adverse events or Japanese encephalitis infections were reported. A 2-dose primary immunization and booster 1 year later with CVI-JE provided long-lasting immunity in the majority of children.

Details

Language :
English
ISSN :
2164-554X
Volume :
18
Issue :
1
Database :
MEDLINE
Journal :
Human vaccines & immunotherapeutics
Publication Type :
Academic Journal
Accession number :
35103548
Full Text :
https://doi.org/10.1080/21645515.2022.2028513